biotech_researcher
5 years ago
Stemlineโs three presentations at ASH in Orlando next week:
Details on the ASH presentations are as follows:
Myelofibrosis โ Clinical (monotherapy); oral presentation
Title: Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Presenter: Naveen Pemmaraju, MD; MD Anderson Cancer Center
Abstract: 558
Session: 634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies
Date/Time: Monday, December 9, 2019 8:15 AM ET
Location: Orange County Convention Center, W304EFGH
Multiple Myeloma โ Clinical (combination therapy); poster presentation
Title: Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Presenter: Paul G. Richardson, M.D.; Dana-Farber Cancer Institute
Abstract: 3145
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Date/Time: Sunday, December 8, 2019 6:00 PMโ8:00 PM ET
Location: Orange County Convention Center, Hall B
Myeloproliferative Neoplasms โ Preclinical (combination therapy); poster presentation
Title: Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms
Presenter: Aishwarya Krishnan, MD; Memorial Sloan Kettering Cancer Center
Abstract: 2967
Session: 635. Myeloproliferative Syndromes: Basic Science: Poster II
Date/Time: Sunday, December 8, 2019 6:00 PMโ8:00 PM ET
Location: Orange County Convention Center, Hall B
whytestocks
5 years ago
News: $STML Stemline Therapeutics to Present at Piper Jaffray's 31st Annual Healthcare Conference
NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Stemline management will present at Piper Jaffray’...
Find out more STML - Stemline Therapeutics to Present at Piper Jaffray's 31st Annual Healthcare Conference
whytestocks
5 years ago
News: $STML Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that clinical data on felezonexor (SL-801) has been selected...
Read the whole news STML - Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress
whytestocks
5 years ago
News: $STML Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...
Find out more STML - Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference
whytestocks
5 years ago
News: $STML Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers for Medicare & Medicaid Services (CMS) g...
Find out more Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®
biotech_researcher
5 years ago
Approved by FDA for BPDCN, rare blood cancer (500-1000 pts annually) with CD113 mutation. No other treatment available. STML has a Very robust pipeline.
$STML Upcoming Tagraxofusp in BPDCN pivotal clinical trial publication in NEJM April 25 edition. No real surprises. Of 29 patients not previously treated, 90% ORR, 13 bridged to transplant, and 52% alive at 2 years. In 13 prev tx'd, ORR=67%, and median OS = 8.5 mos. CLS in 1/44
Lazarus
6 years ago
Now that the stock is in the toilet and the company finally gets an FDA approval its CRICKETS on the board. Too funny. I'm in at $8.07
U.S. FDA approves Stemline Therapeutics' rare blood disease treatment
Dec 21 (Reuters) - The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.
This is the first approved treatment for the condition, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Richard Pazdur, director of the FDA's Oncology Center of Excellence, said.
"The standard of care has been intensive chemotherapy, followed by bone marrow transplantation. Many patients with BPDCN are unable to tolerate this intensive therapy, so there is an urgent need for alternative treatment options."
BPDCN is an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and the skin, the FDA said.
The condition is more common in men than women, and in patients who are 60 years and above.
The labeling for Elzonris contains a boxed warning, FDA's harshest, flagging increased risk of capillary leak syndrome, which may be life-threatening or fatal to patients in treatment.
Stemline Therapeutics shares fell as much as 7.8 percent to $8 in early trading.
cashcow3
8 years ago
Perceptive Advisors LLC bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $115,000. Bogle Investment Management L P DE bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $1,015,000. Renaissance Technologies LLC raised its position in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical companyโs stock worth $701,000 after buying an additional 4,800 shares during the period. Finally, J. Goldman & Co LP bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $2,139,000. Institutional investors own 37.76% of the companyโs stock.